Eaton to Display Terminals and Connectors at CONEXPO-CON/AGG Trade Show
Intelligent power management company Eaton today announced it will be displaying its line of power connectors and terminals for electrified and internal combustion construction and off-highway vehicles at the CONEXPO-CON/AGG construction trade show March 14-18 in Las Vegas.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230309005192/en/
Royal Power Solutions large LP12, LP16 and RD14 terminals are designed for vehicles typically used in construction and off-highway fields. (Photo: Business Wire)
The connectors were designed and developed by Royal Power Solutions (RPS), which Eaton acquired in 2022. Established in 1938, RPS is a global leader in the development and production of critical high-precision power- and signal-distribution terminals and connectors.
“The construction industry, like many others, is transitioning to electrification. Eaton’s global and diverse footprint has broadened our reach and ability to grow in this market,” said Chris Mancuso, general manager, Power Connections, Eaton’s eMobility business. “As the construction industry electrifies, the need for differentiating terminals and connectors evolves in parallel. We have seen a similar transition in the automotive market.”
Eaton’s portfolio of industry-leading electrical solutions includes terminals, connectors and other electrical components designed to handle current levels up to 500 amps. Among those components are stamped battery and eyelet terminals that can withstand vibration and harsh environments, making them ideal for commercial and off-highway vehicles.
High Power Lock Box connectors provide protection, superior performance
Eaton’s high power lock box (HPLB) power connectors are ideal for current and future electrified construction and off-highway vehicle solutions and can help reduce common warranty issues. The HPLB connectors offer a space-saving profile, superior performance, cost savings and reduced manufacturing complexity. The HPLB terminals provide efficiency, reliability and have stronger current carrying capabilities compared to terminals on the market today.
The HPLB terminal system forms a connection in a unique way that provides improved contact force as the temperature increases. Unlike traditional competitors’ box-and-blade or pin-and-socket terminal connections, Eaton’s HPLB terminals use an inverted contact system approach for a stronger connection.
Terminals designed for construction, aggregate industries
Part of the HPLB product line, the low-profile 12 (LP12), low-profile 16 (LP16) and round 14 (RD14) terminals are larger and designed for vehicles typically used in construction and agricultural fields. Able to carry up to 500 amps, the HPLB terminals allow global customers to simplify the manufacturing process and open new areas of opportunity for electrified off-highway vehicles.
Busbars feature low profile, flexibility to meet design requirements
Another technology now available to Eaton’s construction and off-highway vehicle customers is RigiFlex™ busbars, which can be manufactured in copper or aluminum, depending on customer requirements. With a unique, simple, single piece flow manufacturing process, Eaton can scale volume to meet any customer specification.
The RigiFlex™ busbar is rigid in some areas, but flexible in sections that require expansion, contraction or elevated changes in the system design. This flexibility also works well across the battery pack in areas that need to comply with expansion and contraction during charging and discharging cycles due to changing cell thicknesses.
Low-profile busbars enable space-efficient design without heat sinks for weight savings. Eaton also can produce busbars with a level of flatness over length unmatched by competitors.
“When off-highway equipment is assembled, it’s largely done manually since robots have difficulty handling round wires, which are hard for them to grasp,” Mancuso said. “When employing high power lock box terminals our Rigiflex™ busbars improve the assembly process, safety and time to complete the manufacturing process and with less equipment and fewer assembly personnel.”
Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. We are guided by our commitment to do business right, to operate sustainably and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy, helping to solve the world’s most urgent power management challenges, and doing what’s best for our stakeholders and all of society.
Founded in 1911, Eaton is marking its 100th anniversary of being listed on the New York Stock Exchange. We reported revenues of $20.8 billion in 2022 and serve customers in more than 170 countries. For more information, visit www.eaton.com. Follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230309005192/en/
(216) 333-2876 (cell)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RevBio is Awarded a $2 Million Grant to Advance the Development of its Novel Dental Adhesive Bone Scaffold Product8.6.2023 00:12:00 EEST | Press release
RevBio, Inc., announced that it has been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health (NIH). This funding (1R44DE032564-01) will allow the company to complete the pre-clinical research necessary to advance this product into the clinical stage of development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005794/en/ The current standard of care options for rebuilding deficient jawbone includes a variety of materials that require membranes and time consuming fixation devices. These products do not predictably maintain ridge volume which requires surgeons to undergo re-grafting in over 30% of clinical cases. TETRANITE eliminates the use of membranes and other fixation devices, when compared to the standard of care. Furthermore, TETRANITE resorbs fully while maintaining predict
IFF Names New President of Nourish and Introduces Leadership Structure Aligned to New Operating Model7.6.2023 23:18:00 EEST | Press release
IFF (NYSE: IFF) today announced that Yuvraj Arora, currently President, U.S. Categories for Kellogg North America, will join IFF as President, Nourish, effective June 19, 2023. Arora brings more than 25 years of multinational CPG experience to IFF’s Executive Leadership Team, mostly recently leading Kellogg’s $7 billion U.S. portfolio through a period of strong growth and portfolio transformation. IFF today also announced the leadership structure to support the transition to a new operating model as part of the company’s transformation strategy. The shift from its current divisional structure to three core end markets—Food and Beverage, Home and Personal Care, and Health—will provide greater customer intimacy and enhance cross-functional collaboration, allowing for enhanced execution, speed and streamlined delivery. IFF expects its new operating model to be in effect by the beginning of 2024. As President, Nourish, Arora, will lead IFF’s Food and Beverage categories when the operating
Vizgen Issues Open Letter to Customers and Researchers on 10x Genomics June 1, 2023 Lawsuit Announcement in Europe7.6.2023 22:00:00 EEST | Press release
Vizgen, Inc. (“Vizgen” or the “Company”), a life science leader dedicated to improving human health by visualizing single-cell spatial genomics information, today issued the below open letter to customers and researchers in response to 10x Genomics, Inc. (“10x”) filing a lawsuit on June 1, 2023 with the Unified Patent Court (“UPC”) in Europe. *** June 7, 2023 Dear Customers, Researchers and Friends of Vizgen: We are disappointed – though not surprised – that 10x has filed another lawsuit that attempts to undermine innovation, eliminate competition and intimidate both customers and industry peers. Although 10x’s UPC complaint is not yet available to us, we will keep you updated as we learn more. In the meantime, rest assured that we will vigorously defend our shared interests in all proceedings with the UPC, much like we have in the ongoing litigation in the U.S. District Court for the District of Delaware. In the Delaware case, we have gone on the offensive to assert our own countercla
Brenus Pharma announces its international Scientific Committee7.6.2023 19:00:00 EEST | Press release
Following the American Society of Clinical Oncology’s Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow” 1, the company highlighted its international scientific committee. This committee gathering renowned international experts in immuno-oncology, immunotherapies, and novel-treatments is supporting Brenus’ scientific developments of the STCplatform pipeline in solid tumors and its first candidate, STC-1010 targeting colorectal cancer. The committee combined a total of over 1,700 internationally peer-reviewed articles and prestigious awards in the field: Pr François GHIRINGHELLI MD, PhD. Pr of Oncology – Head of “Cancer and adaptative immune response” INSERM, CGFL 2, Dijon. (FR) Head of the Board Pr Ahmad AWADA MD, PhD. Pr of Oncology – Head of Oncology medicine Dept. Jules Bordet Institute-HUB, Brussel. (BE) & Board member Oncodistinct clinical and translational research network, ESMO3 active m
Lunaphore and CST Partnership Advances Spatial Biology Research with Over 1,700 IHC-Validated Antibodies for Use on COMET™7.6.2023 17:00:00 EEST | Press release
Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced a partnership to enable the use of CST® antibodies on the Lunaphore COMET™ platform, a scalable hyperplex imaging solution for fully automated spatial biology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005502/en/ CST is a trusted provider of high-quality, rigorously validated antibodies for immunohistochemistry (IHC) that can detect key proteins in a variety of disease states. This partnership enables the use of over 1,700 IHC-validated antibodies from CST detected by fluorescent secondary antibodies for use on the COMET™, empowering researchers to develop antibody panels quickly and with confidence. With a comprehensive offering of primary rabbit and mous
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom